Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toshiyuki Sasaguri

Showing results (1-10 of 95) with videos related to

Pageof 10
Sort By:
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 1, 2023
[Personal drug education to learn evidence-based medicine]Toshiyuki Sasaguri
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 1, 2023
[Preface]Toshihiko Yanagita, Toshiyuki Sasaguri
Current Vascular Pharmacology|August 24, 2004
Prostaglandin J2 family and the cardiovascular systemToshiyuki Sasaguri, Yoshikazu Miwa
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|March 10, 2010
[Pharmacogenomics of the beta-adrenergic receptor antagonists]Yoshikazu Miwa, Toshiyuki Sasaguri
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|June 20, 2012
[ALDH2 polymorphisms and clinical medicine]Tatsuya Yoshihara, Toshiyuki Sasaguri
Hypertension Research : Official Journal of the Japanese Society of Hypertension|March 18, 2008
Hypoxia-induced cardiac remodeling in sleep apnea syndrome: involvement of the renin-angiotensin-aldosterone systemYoshikazu Miwa, Toshiyuki Sasaguri
Cellular Signalling|November 21, 2007
GSK-3beta regulates cyclin D1 expression: a new target for chemotherapyFumi Takahashi-Yanaga, Toshiyuki Sasaguri
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|May 31, 2007
[Wnt/beta-catenin signaling pathway and drug discovery]Fumi Takahashi-Yanaga, Toshiyuki Sasaguri
Journal of Pharmacological Sciences|August 28, 2007
The Wnt/beta-catenin signaling pathway as a target in drug discoveryFumi Takahashi-Yanaga, Toshiyuki Sasaguri
Journal of Pharmacological Sciences|January 31, 2009
Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugsFumi Takahashi-Yanaga, Toshiyuki Sasaguri
Pageof 10

Showing results (1-10 of 95) with videos related to

Sort By:
Pageof 10
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 1, 2023
[Personal drug education to learn evidence-based medicine]Toshiyuki Sasaguri
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|March 1, 2023
[Preface]Toshihiko Yanagita, Toshiyuki Sasaguri
Current Vascular Pharmacology|August 24, 2004
Prostaglandin J2 family and the cardiovascular systemToshiyuki Sasaguri, Yoshikazu Miwa
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|March 10, 2010
[Pharmacogenomics of the beta-adrenergic receptor antagonists]Yoshikazu Miwa, Toshiyuki Sasaguri
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|June 20, 2012
[ALDH2 polymorphisms and clinical medicine]Tatsuya Yoshihara, Toshiyuki Sasaguri
Hypertension Research : Official Journal of the Japanese Society of Hypertension|March 18, 2008
Hypoxia-induced cardiac remodeling in sleep apnea syndrome: involvement of the renin-angiotensin-aldosterone systemYoshikazu Miwa, Toshiyuki Sasaguri
Cellular Signalling|November 21, 2007
GSK-3beta regulates cyclin D1 expression: a new target for chemotherapyFumi Takahashi-Yanaga, Toshiyuki Sasaguri
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|May 31, 2007
[Wnt/beta-catenin signaling pathway and drug discovery]Fumi Takahashi-Yanaga, Toshiyuki Sasaguri
Journal of Pharmacological Sciences|August 28, 2007
The Wnt/beta-catenin signaling pathway as a target in drug discoveryFumi Takahashi-Yanaga, Toshiyuki Sasaguri
Journal of Pharmacological Sciences|January 31, 2009
Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugsFumi Takahashi-Yanaga, Toshiyuki Sasaguri
Pageof 10